Journal of Clinical Oncology, Vol 14, 2756-2768, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study

MA Sprangers, M Groenvold, JI Arraras, J Franklin, A te Velde, M Muller, L Franzini, A Williams, HC de Haes, P Hopwood, A Cull and NK Aaronson
Netherlands Cancer Institute, Amsterdam, The Netherlands. M.A.Sprangers@AMC.UVA.NL

PURPOSE: To construct a breast cancer-specific quality-of-life questionnaire (QLQ) module to be used in conjunction with the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and to test its reliability and validity cross-culturally. PATIENTS AND METHODS: Module construction took place after the EORTC guidelines for module development. The module--the QLQ-BR23--consists of 23 items covering symptoms and side effects related to different treatment modalities, body image, sexuality, and future perspective. This module was tested in 170 Dutch, 168 Spanish, and 158 American cancer patients at two points in time. The timing for the Dutch and Spanish patients was before and during treatment with radiotherapy or chemotherapy. For the American patients, the questionnaire was administered at admission at the breast clinic and 3 months after the first assessment. RESULTS: Multitrait scaling analysis confirmed the hypothesized structure of four of the five scales. Cronbach's alpha coefficients were, in general, lowest in Spain (range; .46 to .94) and highest in the United States (range; .70 to .91). On the basis of known-groups comparisons, selective scales distinguished clearly between patients differing in disease stage, previous surgery, performance status, and treatment modality, according to expectation. Additionally, selective scales detected change over time as a function of changes in performance status and treatment-induced change. CONCLUSION: These results lend support to the clinical and cross-cultural validity of the QLQ-BR23 as a supplementary questionnaire for assessing specific quality-of-life issues relevant to patients with breast cancer.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Wan, Q. Meng, Z. Yang, X. Tu, C. Feng, X. Tang, and C. Zhang Validation of the simplified Chinese version of EORTC QLQ-C30 from the measurements of five types of inpatients with cancer Ann. Onc., December 1, 2008; 19(12): 2053 - 2060. [Abstract] [Full Text] [PDF]

				J.-P. Pignol, I. Olivotto, E. Rakovitch, S. Gardner, K. Sixel, W. Beckham, T. T. T. Vu, P. Truong, I. Ackerman, and L. Paszat A Multicenter Randomized Trial of Breast Intensity-Modulated Radiation Therapy to Reduce Acute Radiation Dermatitis J. Clin. Oncol., May 1, 2008; 26(13): 2085 - 2092. [Abstract] [Full Text] [PDF]

				M. van Seters, M. van Beurden, F. J.W. ten Kate, I. Beckmann, P. C. Ewing, M. J.C. Eijkemans, M. J. Kagie, C. J.M. Meijer, N. K. Aaronson, A. KleinJan, et al. Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod N. Engl. J. Med., April 3, 2008; 358(14): 1465 - 1473. [Abstract] [Full Text] [PDF]

				J. Lipscomb, C. C. Gotay, and C. F. Snyder Patient-reported Outcomes in Cancer: A Review of Recent Research and Policy Initiatives CA Cancer J Clin, September 1, 2007; 57(5): 278 - 300. [Abstract] [Full Text] [PDF]

				The Adjuvant Breast Cancer Trials Collaborative Gr Polychemotherapy for Early Breast Cancer: Results From the International Adjuvant Breast Cancer Chemotherapy Randomized Trial J Natl Cancer Inst, April 4, 2007; 99(7): 506 - 515. [Abstract] [Full Text] [PDF]

				F Efficace, D Osoba, C Gotay, M Sprangers, C Coens, and A Bottomley Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making Ann. Onc., April 1, 2007; 18(4): 775 - 781. [Abstract] [Full Text] [PDF]

				J. F. Waljee, M. A.M. Rogers, and A. K. Alderman Decision Aids and Breast Cancer: Do They Influence Choice for Surgery and Knowledge of Treatment Options? J. Clin. Oncol., March 20, 2007; 25(9): 1067 - 1073. [Abstract] [Full Text] [PDF]

				S. Ahn, B. Park, D. Noh, S. Nam, E. Lee, M. Lee, S. Kim, K. Lee, S. Park, and Y. Yun Health-related quality of life in disease-free survivors of breast cancer with the general population Ann. Onc., January 1, 2007; 18(1): 173 - 182. [Abstract] [Full Text] [PDF]

				C. J. Poole, H. M. Earl, L. Hiller, J. A. Dunn, S. Bathers, R. J. Grieve, D. A. Spooner, R. K. Agrawal, I. N. Fernando, A. M. Brunt, et al. Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer N. Engl. J. Med., November 2, 2006; 355(18): 1851 - 1862. [Abstract] [Full Text] [PDF]

				M. Martin, A. Lluch, M. A. Segui, A. Ruiz, M. Ramos, E. Adrover, A. Rodriguez-Lescure, R. Grosse, L. Calvo, C. Fernandez-Chacon, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen Ann. Onc., August 1, 2006; 17(8): 1205 - 1212. [Abstract] [Full Text] [PDF]

				V. Arndt, H. Merx, C. Stegmaier, H. Ziegler, and H. Brenner Persistence of Restrictions in Quality of Life From the First to the Third Year After Diagnosis in Women With Breast Cancer J. Clin. Oncol., August 1, 2005; 23(22): 4945 - 4953. [Abstract] [Full Text] [PDF]

				E. A. Hahn, B. Holzner, G. Kemmler, B. Sperner-Unterweger, S. A. Hudgens, and D. Cella Cross-Cultural Evaluation of Health Status Using Item Response Theory: FACT-B Comparisons Between Austrian and U.S. Patients With Breast Cancer Eval Health Prof, June 1, 2005; 28(2): 233 - 259. [Abstract] [PDF]

				M. Okamura, S. Yamawaki, T. Akechi, K. Taniguchi, and Y. Uchitomi Psychiatric Disorders Following First Breast Cancer Recurrence: Prevalence, Associated Factors and Relationship to Quality of Life Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 302 - 309. [Abstract] [Full Text] [PDF]

				O. Feher, P. Vodvarka, J. Jassem, G. Morack, S. H. Advani, K. S. Khoo, D. C. Doval, S. Ermisch, D. Roychowdhury, M. A. Miller, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study Ann. Onc., June 1, 2005; 16(6): 899 - 908. [Abstract] [Full Text] [PDF]

				J. Mandelblatt, C. Armetta, K. R. Yabroff, W. Liang, and W. Lawrence Descriptive Review of the Literature on Breast Cancer Outcomes: 1990 Through 2000 J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 8 - 44. [Abstract] [Full Text] [PDF]

				A. Bottomley, L. Biganzoli, T. Cufer, R. E. Coleman, C. Coens, F. Efficace, H. A. Calvert, T. Gamucci, C. Twelves, P. Fargeot, et al. Randomized, Controlled Trial Investigating Short-Term Health-Related Quality of Life With Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study J. Clin. Oncol., July 1, 2004; 22(13): 2576 - 2586. [Abstract] [Full Text] [PDF]

				P. G. Gill Sentinel Lymph Node Biopsy Versus Axillary Clearance in Operable Breast Cancer: The RACS SNAC Trial, A Multicenter Randomized Trial of the Royal Australian College of Surgeons (RACS) Section of Breast Surgery, in Collaboration with the National Health and Medical Research Council Clinical Trials Center Ann. Surg. Oncol., March 1, 2004; 11(3_suppl): 216S - 221S. [Abstract] [Full Text] [PDF]

				L. Reyno, L. Seymour, D. Tu, S. Dent, K. Gelmon, B. Walley, A. Pluzanska, V. Gorbunova, A. Garin, J. Jassem, et al. Phase III Study of N,N-Diethyl-2-[4-(Phenylmethyl) Phenoxy]Ethanamine (BMS-217380-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19 J. Clin. Oncol., January 15, 2004; 22(2): 269 - 276. [Abstract] [Full Text] [PDF]

				J. M. Watters, J. C. Yau, K. O'Rourke, E. Tomiak, and S. Z. Gertler Functional status is well maintained in older women during adjuvant chemotherapy for breast cancer Ann. Onc., December 1, 2003; 14(12): 1744 - 1750. [Abstract] [Full Text] [PDF]

				Y. Brandberg, H. Michelson, B. Nilsson, C. Bolund, B. Erikstein, P. Hietanen, S. Kaasa, J. Nilsson, T. Wiklund, N. Wilking, et al. Quality of Life in Women With Breast Cancer During the First Year After Random Assignment to Adjuvant Treatment With Marrow-Supported High-Dose Chemotherapy With Cyclophosphamide, Thiotepa, and Carboplatin or Tailored Therapy With Fluorouracil, Epirubicin, and Cyclophosphamide: Scandinavian Breast Group Study 9401 J. Clin. Oncol., October 1, 2003; 21(19): 3659 - 3664. [Abstract] [Full Text] [PDF]

				K. Hartl, W. Janni, R. Kastner, H. Sommer, B. Strobl, B. Rack, and M. Stauber Impact of medical and demographic factors on long-term quality of life and body image of breast cancer patients Ann. Onc., July 1, 2003; 14(7): 1064 - 1071. [Abstract] [Full Text] [PDF]

				A. Buzdar, J. Douma, N. Davidson, R. Elledge, M. Morgan, R. Smith, L. Porter, J. Nabholtz, X. Xiang, and C. Brady Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol Acetate J. Clin. Oncol., July 15, 2001; 19(14): 3357 - 3366. [Abstract] [Full Text] [PDF]

				B. Holzner, G. Kemmler, M. Kopp, R. Moschen, H. Schweigkofler, M. Dünser, R. Margreiter, W. W. Fleischhacker, and B. Sperner-Unterweger Quality of Life in Breast Cancer Patients--Not Enough Attention for Long-Term Survivors? Psychosomatics, April 1, 2001; 42(2): 117 - 123. [Abstract] [Full Text]

				S. Molenaar, M. A. Sprangers, E. J. Th. Rutgers, E. J. Luiten, J. Mulder, P. M. Bossuyt, J. J. van Everdingen, P. Oosterveld, and H. C. de Haes Decision Support for Patients With Early-Stage Breast Cancer: Effects of an Interactive Breast Cancer CDROM on Treatment Decision, Satisfaction, and Quality of Life J. Clin. Oncol., March 15, 2001; 19(6): 1676 - 1687. [Abstract] [Full Text] [PDF]

				G. Macquart-Moulin, P. Viens, T. Palangie, M.-L. Bouscary, T. Delozier, H. Roche, M. Janvier, M. Fabbro, and J.-P. Moatti High-Dose Sequential Chemotherapy With Recombinant Granulocyte Colony-Stimulating Factor and Repeated Stem-Cell Support for Inflammatory Breast Cancer Patients: Does Impact on Quality of Life Jeopardize Feasibility and Acceptability of Treatment? J. Clin. Oncol., February 14, 2000; 18(4): 754 - 754. [Abstract] [Full Text] [PDF]

				G. Kemmler, B. Holzner, M. Kopp, M. Dunser, R. Margreiter, R. Greil, and B. Sperner-Unterweger Comparison of Two Quality-of-Life Instruments for Cancer Patients: The Functional Assessment of Cancer Therapy-General and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 J. Clin. Oncol., September 1, 1999; 17(9): 2932 - 2932. [Abstract] [Full Text] [PDF]

				K. Bjordal, E. Hammerlid, M. Ahlner-Elmqvist, A. de Graeff, M. Boysen, J. F. Evensen, A. Biorklund, J. R. J. de Leeuw, P. M. Fayers, M. Jannert, et al. Quality of Life in Head and Neck Cancer Patients: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35 J. Clin. Oncol., March 1, 1999; 17(3): 1008 - 1008. [Abstract] [Full Text] [PDF]

				C. C. Gotay and M. Wilson Use of Quality-of-Life Outcome Assessments in Current Cancer Clinical Trials Eval Health Prof, June 1, 1998; 21(2): 157 - 178. [Abstract] [PDF]